{"hands_on_practices": [{"introduction": "A cornerstone of cell biology research is the ability to interpret multi-faceted experimental data to deduce underlying cellular processes. This exercise challenges you to act as an experimentalist, piecing together evidence from standard molecular assays to distinguish between apoptosis, autophagy, and necrosis. By analyzing changes in established biomarkers in response to a hypothetical stressor and specific inhibitors, you will practice the critical reasoning required to build a mechanistic model of a cell's fate [@problem_id:2603013].", "problem": "A mammalian cell line is exposed to a small-molecule stressor, Treatment X, and monitored over time for hallmarks of regulated cell death and autophagy. The following readouts are collected with appropriate controls:\n\n- Annexin V binding to externalized phosphatidylserine (percentage of Annexin V positive cells).\n- Cleavage of caspase-3 (immunoblot).\n- Microtubule-associated protein 1A/1B-light chain 3 (LC3) lipidation (LC3-II accumulation by immunoblot).\n- Autophagy receptor sequestosome 1 (p62/SQSTM1) abundance by immunoblot.\n- Propidium Iodide (PI) uptake (percentage of PI positive cells).\n- Lysosomal inhibition using bafilomycin A1 applied 1 h before readout.\n- A broad-spectrum caspase inhibitor applied 1 h before Treatment X.\n- Nutrient starvation as a positive control for autophagic flux.\n\nObserved outcomes (means across 3 independent experiments):\n\n- Untreated control at $t=6$ h: Annexin V $\\approx 3\\%$, PI $\\approx 1\\%$, caspase-3 cleavage absent, LC3-II low, p62 stable.\n- Treatment X at $t=6$ h: Annexin V $\\approx 45\\%$, PI $\\approx 8\\%$, robust caspase-3 cleavage, LC3-II increased $\\approx 2.5\\times$ relative to control, p62 decreased to $\\approx 50\\%$ of control.\n- Treatment X at $t=16$ h: Annexin V $\\approx 70\\%$, PI $\\approx 60\\%$, caspase-3 cleavage persists.\n- Treatment X at $t=6$ h plus lysosomal inhibition: LC3-II further increased to $\\approx 5\\times$ control, p62 rose to $\\approx 1.5\\times$ control, Annexin V $\\approx 60\\%$, PI $\\approx 20\\%$.\n- Treatment X at $t=16$ h plus lysosomal inhibition: Annexin V $\\approx 80\\%$, PI $\\approx 75\\%$.\n- Treatment X at $t=6$ h plus broad-spectrum caspase inhibitor: caspase-3 cleavage undetectable, Annexin V $\\approx 15\\%$, PI $\\approx 5\\%$, LC3-II increased $\\approx 2\\times$, p62 decreased to $\\approx 60\\%$ of control.\n- Starvation at $t=6$ h: LC3-II increased $\\approx 2\\times$ control, p62 decreased to $\\approx 60\\%$ of control; with lysosomal inhibition, starvation further increased LC3-II and prevented p62 degradation.\n\nUsing only fundamental definitions of apoptosis and autophagy and widely accepted biomarker behavior (for example, phosphatidylserine externalization in apoptosis, plasma membrane integrity loss in necrosis, LC3-II and p62 dynamics as readouts of autophagic flux), infer the dominant pathway governing the fate of cells under Treatment X and defend your inference against the most plausible alternative explanations consistent with the data. Choose the single best interpretation:\n\nA. Classical caspase-dependent apoptosis is the dominant mode of death; autophagy is a cytoprotective response with increased autophagic flux.\n\nB. Autophagic cell death is dominant; apoptosis is secondary or bystander.\n\nC. Primary necrosis is dominant; autophagy is impaired (flux blocked), contributing to toxicity.\n\nD. Caspase-independent apoptosis, mediated by Apoptosis-Inducing Factor (AIF), is dominant, and autophagy is neutral.\n\nE. Mixed-mode death dominated by autophagy impairment; LC3-II accumulation reflects blocked flux that directly drives death.", "solution": "The problem statement is a valid, well-posed exercise in the interpretation of experimental data in cellular biology. All provided data and experimental designs are consistent with established scientific principles and standard laboratory practices for investigating apoptosis and autophagy.\n\nThe analysis proceeds by systematically interpreting the provided experimental outcomes in the context of canonical cell death and autophagy pathways.\n\n1.  **Analysis of the Cell Death Pathway**\n\nThe data provide multiple, consistent lines of evidence pointing to caspase-dependent apoptosis as the primary mode of cell death induced by Treatment X.\n\n-   **Phosphatidylserine (PS) Externalization and Membrane Integrity**: Apoptosis is initiated by a series of signaling events culminating in the externalization of PS, which is detected by Annexin V binding, while the plasma membrane initially remains intact. Necrosis, by contrast, involves early loss of membrane integrity, detected by Propidium Iodide (PI) uptake.\n    -   At $t=6$ h, Treatment X induces a large population of Annexin V-positive cells ($\\approx 45\\%$) but a much smaller population of PI-positive cells ($\\approx 8\\%$). This large Annexin V$^+$/PI$^-$ population is the classic signature of early-stage apoptosis.\n    -   At $t=16$ h, both Annexin V ($\\approx 70\\%$) and PI ($\\approx 60\\%$) positivity are high. This indicates progression from early apoptosis to late apoptosis and secondary necrosis, where membrane integrity is eventually lost. This kinetic profile is inconsistent with primary necrosis.\n\n-   **Caspase-3 Activation**: Caspase-3 is a critical executioner caspase in the apoptotic cascade. The observation of \"robust caspase-3 cleavage\" following Treatment X is a definitive molecular hallmark of apoptosis.\n\n-   **Effect of Caspase Inhibition**: The most conclusive evidence comes from the use of a broad-spectrum caspase inhibitor. When applied before Treatment X, the inhibitor \"dramatically\" reduces cell death at $t=6$ h: Annexin V positivity drops from $\\approx 45\\%$ to $\\approx 15\\%$ and PI positivity drops from $\\approx 8\\%$ to $\\approx 5\\%$. This demonstrates that the majority of the observed cell death is dependent on caspase activity. The small amount of residual death may suggest a minor caspase-independent component or incomplete inhibition, but the dominant pathway is unequivocally caspase-dependent apoptosis.\n\n2.  **Analysis of the Autophagy Pathway**\n\nThe data indicate that Treatment X induces a functional and complete autophagic response, characterized by increased autophagic flux.\n\n-   **Autophagy Markers**: The level of lipidated LC3 (LC3-II) reflects the number of autophagosomes. The level of the autophagy receptor p62/SQSTM1 is inversely correlated with autophagic flux, as p62 itself is degraded within autolysosomes.\n    -   With Treatment X alone, LC3-II levels increase ($\\approx 2.5\\times$) while p62 levels decrease (to $\\approx 50\\%$). This combination is the canonical indicator of an increase in autophagic flux (i.e., the entire process from autophagosome formation to degradation is active and accelerated). The starvation positive control confirms this interpretation.\n\n-   **Autophagic Flux Assay with Lysosomal Inhibition**: To distinguish between increased autophagy induction and a block in autophagosome degradation, a lysosomal inhibitor like bafilomycin A1 is used. Bafilomycin A1 prevents the degradation of autophagosomes.\n    -   In the presence of bafilomycin A1, LC3-II levels under Treatment X increase even further (from $\\approx 2.5\\times$ to $\\approx 5\\times$ control). This \"further accumulation\" is the gold-standard evidence for active autophagic flux; it indicates that autophagosomes are being continuously generated and would have been degraded if the lysosome were functional.\n    -   Furthermore, bafilomycin A1 prevents the degradation of p62, causing its levels to rise ($\\approx 1.5\\times$ control). This confirms that p62 is indeed being cleared by lysosome-dependent autophagy under Treatment X.\n    -   Therefore, the data conclusively show that autophagy is not blocked or impaired; rather, autophagic flux is robustly induced.\n\n3.  **Analysis of the Crosstalk between Apoptosis and Autophagy**\n\nThe final step is to determine the relationship between the two induced pathways. Autophagy can be pro-survival (cytoprotective), pro-death, or contextually neutral.\n\n-   The experiment combining Treatment X with bafilomycin A1 provides the key insight. Inhibiting the final, degradative step of autophagy with bafilomycin A1 leads to a significant increase in cell death at $t=6$ h (Annexin V increases from $\\approx 45\\%$ to $\\approx 60\\%$, and PI from $\\approx 8\\%$ to $\\approx 20\\%$).\n-   This result demonstrates that a functional autophagic pathway serves to protect the cells from the stress induced by Treatment X. When this protective mechanism is blocked, the cells are more susceptible to death. Hence, autophagy is acting in a cytoprotective capacity.\n\n**Evaluation of Options**\n\n-   **A. Classical caspase-dependent apoptosis is the dominant mode of death; autophagy is a cytoprotective response with increased autophagic flux.**\n    -   This statement is fully supported by all points of the analysis. Apoptosis is caspase-dependent and dominant. Autophagic flux is increased. Autophagy is cytoprotective.\n    -   **Verdict: Correct.**\n\n-   **B. Autophagic cell death is dominant; apoptosis is secondary or bystander.**\n    -   This is incorrect. The data show overwhelming evidence for apoptosis (caspase-3 cleavage, rescue by caspase inhibitor). Furthermore, the data suggest autophagy is cytoprotective, not a cause of death.\n    -   **Verdict: Incorrect.**\n\n-   **C. Primary necrosis is dominant; autophagy is impaired (flux blocked), contributing to toxicity.**\n    -   This is incorrect. The Annexin V/PI kinetics rule out primary necrosis. The autophagic flux analysis shows flux is increased, not blocked.\n    -   **Verdict: Incorrect.**\n\n-   **D. Caspase-independent apoptosis, mediated by Apoptosis-Inducing Factor (AIF), is dominant, and autophagy is neutral.**\n    -   This is incorrect. The dominance of caspase-dependent death is proven by the inhibitor experiment. Autophagy is not neutral; it is demonstrably cytoprotective.\n    -   **Verdict: Incorrect.**\n\n-   **E. Mixed-mode death dominated by autophagy impairment; LC3-II accumulation reflects blocked flux that directly drives death.**\n    -   This is incorrect. Autophagic flux is clearly increased, not impaired. The premise that blocked flux drives death is contradicted by the finding that autophagy is cytoprotective.\n    -   **Verdict: Incorrect.**\n\nThe only interpretation that coherently integrates all provided experimental data is A. Treatment X induces a classical apoptotic cell death program while cells simultaneously mount a cytoprotective autophagic response in an attempt to survive.", "answer": "$$\\boxed{A}$$", "id": "2603013"}, {"introduction": "After identifying a key pathway, a quantitative understanding of its core components provides deeper insight. This practice moves from qualitative observation to computational modeling of the apoptosome, the central executioner complex in intrinsic apoptosis. You will translate the principles of cooperative oligomerization and allosteric activation by cytochrome $c$ and ATP into a mathematical model, exploring how this molecular machine functions as a decisive, switch-like device in the cell's life-or-death decision [@problem_id:2602955].", "problem": "You are asked to implement a physically realistic, probabilistic model of apoptosome assembly under varying biochemical conditions, grounded in the regulation of apoptosis through Apoptotic protease activating factor 1 (Apaf-1) and its oligomerization into the heptameric apoptosome. Mutations in the Caspase Recruitment Domain (CARD) of Apaf-1 are known to reduce oligomerization efficiency. Your task is to mathematically model and compute how the probability of apoptosome assembly depends on cytochrome $c$ concentration and Adenosine triphosphate (ATP) concentration, while accounting for CARD-domain mutations as a reduction in the effective oligomerization equilibrium constant.\n\nStart from the following fundamental base:\n- Law of mass action for single-site ligand binding and oligomerization equilibria.\n- The definition that the fractional occupancy of a single binding site at equilibrium follows from mass action, and that multi-subunit complex formation at equilibrium can be modeled as an association reaction with a well-defined equilibrium constant.\n\nModel assumptions to be used:\n- Activation of Apaf-1 requires both cytochrome $c$ and ATP to bind. Assume independent binding events for cytochrome $c$ and ATP on Apaf-1; thus the activation probability is the product of the individual binding probabilities derived from single-site equilibrium binding under mass action.\n- Only activated Apaf-1 monomers can oligomerize. Denote activated monomers as species $A$. The oligomerization reaction is a single-step association of $7$ activated monomers into the heptameric apoptosome $H$:\n$$7A \\rightleftharpoons H,$$\nwith equilibrium constant\n$$K_7 = \\frac{[H]}{[A]^7}.$$\n- A CARD-domain mutation reduces $K_7$ by a multiplicative factor $\\gamma \\in (0,1]$, so that the effective constant is $K_7^{\\mathrm{eff}} = \\gamma\\,K_7^{\\mathrm{WT}}$.\n- Let the total concentration of Apaf-1 be $[A]_{\\mathrm{tot}}$ and define the total concentration of activated Apaf-1 as $[A]_{\\mathrm{act,tot}} = p_{\\mathrm{act}}\\,[A]_{\\mathrm{tot}}$, where $p_{\\mathrm{act}}$ is the activation probability derived from binding equilibria. Within the activated sub-pool, the mass balance is\n$[A]_{\\mathrm{act,tot}} = [A] + 7[H]$, with $[H] = K_7^{\\mathrm{eff}} [A]^7$.\n- Define the apoptosome assembly probability as the fraction of activated Apaf-1 found in the heptameric complex,\n$$P_{\\mathrm{assembly}} = \\frac{7[H]}{[A]_{\\mathrm{act,tot}}}.$$\n\nParameters to be used (all concentrations in micromolar, $\\mu$M):\n- Cytochrome $c$ dissociation constant for Apaf-1: $K_d^{c} = 0.05$ $\\mu$M.\n- ATP dissociation constant for Apaf-1: $K_d^{a} = 200.0$ $\\mu$M.\n- Wild-type heptamerization equilibrium constant: $K_7^{\\mathrm{WT}} = 1.0 \\times 10^{5}$ $\\mu$M$^{-6}$.\n- Total Apaf-1 concentration: $[A]_{\\mathrm{tot}} = 0.2$ $\\mu$M.\n\nRequired derivations and computations:\n- Let $[C]$ denote cytochrome $c$ concentration and $[T]$ denote ATP concentration (both in $\\mu$M). Under single-site binding with mass action, compute the binding probabilities for cytochrome $c$ and ATP, and then compute the activation probability $p_{\\mathrm{act}}$ as the product of the two.\n- Compute $[A]_{\\mathrm{act,tot}} = p_{\\mathrm{act}}\\,[A]_{\\mathrm{tot}}$.\n- For a given $\\gamma$, define $K_7^{\\mathrm{eff}} = \\gamma\\,K_7^{\\mathrm{WT}}$ and solve the mass balance for $[A]$ using\n$$[A] + 7 K_7^{\\mathrm{eff}} [A]^7 - [A]_{\\mathrm{act,tot}} = 0,$$\non the interval $[0,[A]_{\\mathrm{act,tot}}]$.\n- Compute $[H] = K_7^{\\mathrm{eff}} [A]^7$ and output the apoptosome assembly probability\n$$P_{\\mathrm{assembly}} = \\frac{7[H]}{[A]_{\\mathrm{act,tot}}}.$$\n- Handle boundary cases where $p_{\\mathrm{act}} = 0$ by defining $P_{\\mathrm{assembly}} = 0$.\n\nTest suite:\nFor each test case, inputs are triples $\\big([C], [T], \\gamma\\big)$ with $[C]$ in $\\mu$M, $[T]$ in $\\mu$M, and $\\gamma$ dimensionless. Use the following eight test cases, in the order listed:\n- Case 1: $\\big(0.01, 2000.0, 1.0\\big)$\n- Case 2: $\\big(0.5, 2000.0, 1.0\\big)$\n- Case 3: $\\big(1.0, 2000.0, 1.0\\big)$\n- Case 4: $\\big(0.5, 100.0, 1.0\\big)$\n- Case 5: $\\big(1.0, 10.0, 1.0\\big)$\n- Case 6: $\\big(0.5, 2000.0, 0.5\\big)$\n- Case 7: $\\big(0.5, 2000.0, 0.1\\big)$\n- Case 8: $\\big(0.0, 2000.0, 1.0\\big)$\n\nProgram requirements:\n- Your program must compute $P_{\\mathrm{assembly}}$ for each test case using the model above and produce a single line of output containing the results as a comma-separated list enclosed in square brackets, in the same order as the test cases, with each value rounded to $6$ decimal places, for example, $\\big[x_1,x_2,\\dots\\big]$.\n- All concentrations must be handled in $\\mu$M. The final $P_{\\mathrm{assembly}}$ is unitless. No angles or percentages are involved.", "solution": "The problem is subjected to rigorous validation and is deemed valid. It is scientifically grounded in the principles of chemical equilibrium, well-posed from a mathematical standpoint, and presents a clear, objective, and complete set of instructions for modeling a key process in apoptosis. The parameters provided are biochemically plausible, and the task is a non-trivial application of biophysical modeling principles.\n\nThe solution proceeds by first deriving the necessary mathematical expressions from the stated principles, then outlining the numerical procedure for computation.\n\n**Step 1: Apaf-1 Activation Probability**\n\nThe activation of an Apoptotic protease activating factor 1 (Apaf-1) monomer is contingent upon the binding of both cytochrome $c$ (denoted C) and Adenosine triphosphate (ATP, denoted T). The problem states these are independent binding events. The probability of each binding event is modeled using the law of mass action for single-site binding.\n\nFor a generic ligand $L$ binding to a receptor $R$ with dissociation constant $K_d$, the reaction is $R + L \\rightleftharpoons RL$. The fractional occupancy, which represents the probability of binding at equilibrium, is given by:\n$$\np_{\\mathrm{bind}} = \\frac{[RL]}{[R]_{\\mathrm{total}}} = \\frac{[L]}{[L] + K_d}\n$$\nApplying this to our system:\nThe probability of cytochrome $c$ binding, $p_{\\mathrm{bind},c}$, depends on its concentration $[C]$ and its dissociation constant for Apaf-1, $K_d^c = 0.05 \\, \\mu\\text{M}$.\n$$\np_{\\mathrm{bind},c} = \\frac{[C]}{[C] + K_d^c}\n$$\nThe probability of ATP binding, $p_{\\mathrm{bind},a}$, depends on its concentration $[T]$ and its dissociation constant for Apaf-1, $K_d^a = 200.0 \\, \\mu\\text{M}$.\n$$\np_{\\mathrm{bind},a} = \\frac{[T]}{[T] + K_d^a}\n$$\nSince the binding events are independent, the total probability of an Apaf-1 monomer being activated, $p_{\\mathrm{act}}$, is the product of these individual probabilities:\n$$\np_{\\mathrm{act}} = p_{\\mathrm{bind},c} \\cdot p_{\\mathrm{bind},a} = \\left( \\frac{[C]}{[C] + K_d^c} \\right) \\left( \\frac{[T]}{[T] + K_d^a} \\right)\n$$\n\n**Step 2: Mass Balance and Oligomerization Equilibrium**\n\nOnly activated Apaf-1 monomers, denoted as species $A$, can participate in oligomerization. The total concentration of potentially active monomers, $[A]_{\\mathrm{act,tot}}$, is the fraction $p_{\\mathrm{act}}$ of the total Apaf-1 concentration, $[A]_{\\mathrm{tot}} = 0.2 \\, \\mu\\text{M}$.\n$$\n[A]_{\\mathrm{act,tot}} = p_{\\mathrm{act}} \\cdot [A]_{\\mathrm{tot}}\n$$\nThese activated monomers exist in equilibrium with the fully assembled heptameric apoptosome, $H$. The oligomerization is modeled as a single-step reaction involving $7$ monomers:\n$$\n7A \\rightleftharpoons H\n$$\nThe equilibrium is described by the effective equilibrium constant $K_7^{\\mathrm{eff}}$:\n$$\nK_7^{\\mathrm{eff}} = \\frac{[H]}{[A]^7}\n$$\nwhere $[A]$ is the concentration of free (un-oligomerized) activated monomers and $[H]$ is the concentration of the heptamer. A CARD-domain mutation is modeled as a reduction of the wild-type constant $K_7^{\\mathrm{WT}} = 1.0 \\times 10^5 \\, \\mu\\text{M}^{-6}$ by a factor $\\gamma \\in (0,1]$:\n$$\nK_7^{\\mathrm{eff}} = \\gamma \\cdot K_7^{\\mathrm{WT}}\n$$\nThe law of mass conservation must hold for the activated Apaf-1 pool. The total concentration of activated Apaf-1, $[A]_{\\mathrm{act,tot}}$, is distributed between the free monomers $[A]$ and those incorporated into the heptamer, $7[H]$.\n$$\n[A]_{\\mathrm{act,tot}} = [A] + 7[H]\n$$\nSubstituting the equilibrium expression for $[H] = K_7^{\\mathrm{eff}}[A]^7$ into the mass balance equation gives a governing equation for the free monomer concentration $[A]$:\n$$\n[A]_{\\mathrm{act,tot}} = [A] + 7 K_7^{\\mathrm{eff}} [A]^7\n$$\nThis can be rearranged into a polynomial equation that must be solved for $[A]$:\n$$\n7 K_7^{\\mathrm{eff}} [A]^7 + [A] - [A]_{\\mathrm{act,tot}} = 0\n$$\n\n**Step 3: Apoptosome Assembly Probability**\n\nThe apoptosome assembly probability, $P_{\\mathrm{assembly}}$, is defined as the fraction of activated Apaf-1 that is incorporated into the heptameric complex.\n$$\nP_{\\mathrm{assembly}} = \\frac{7[H]}{[A]_{\\mathrm{act,tot}}}\n$$\nUsing the mass balance equation $[A]_{\\mathrm{act,tot}} = [A] + 7[H]$, we can express $7[H]$ as $[A]_{\\mathrm{act,tot}} - [A]$. Substituting this into the definition of $P_{\\mathrm{assembly}}$ provides a more direct and numerically stable way to calculate the result once $[A]$ is known:\n$$\nP_{\\mathrm{assembly}} = \\frac{[A]_{\\mathrm{act,tot}} - [A]}{[A]_{\\mathrm{act,tot}}} = 1 - \\frac{[A]}{[A]_{\\mathrm{act,tot}}}\n$$\nThis expression is valid for $[A]_{\\mathrm{act,tot}} > 0$. For the boundary case where $[A]_{\\mathrm{act,tot}} = 0$ (which occurs if $[C]=0$ or $[T]=0$), the problem explicitly defines $P_{\\mathrm{assembly}} = 0$.\n\n**Step 4: Numerical Solution**\n\nFor each test case $(\\,[C], [T], \\gamma\\,)$, the procedure is as follows:\n1.  Calculate $p_{\\mathrm{act}}$ and subsequently $[A]_{\\mathrm{act,tot}}$. If $[A]_{\\mathrm{act,tot}} = 0$, the result is $P_{\\mathrm{assembly}} = 0$.\n2.  If $[A]_{\\mathrm{act,tot}} > 0$, calculate $K_7^{\\mathrm{eff}}$.\n3.  Solve the seventh-degree polynomial equation $f([A]) = 7 K_7^{\\mathrm{eff}} [A]^7 + [A] - [A]_{\\mathrm{act,tot}} = 0$ for $[A]$.\n    - The function $f([A])$ is strictly monotonically increasing for $[A] \\ge 0$, as its derivative $f'([A]) = 49 K_7^{\\mathrm{eff}} [A]^6 + 1$ is always positive.\n    - At the boundaries of the physical domain $[0, [A]_{\\mathrm{act,tot}}]$, we have $f(0) = -[A]_{\\mathrm{act,tot}} \\le 0$ and $f([A]_{\\mathrm{act,tot}}) = 7 K_7^{\\mathrm{eff}} ([A]_{\\mathrm{act,tot}})^7 \\ge 0$.\n    - These properties guarantee a unique real root for $[A]$ within the interval $[0, [A]_{\\mathrm{act,tot}}]$. A robust numerical root-finding algorithm, such as Brent's method, is suitable for this task.\n4.  Compute $P_{\\mathrm{assembly}} = 1 - \\frac{[A]}{[A]_{\\mathrm{act,tot}}}$.\n\nThis systematic procedure will be implemented to compute the results for the given test suite.", "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\nfrom scipy.optimize import brentq\n\ndef solve():\n    \"\"\"\n    Computes the apoptosome assembly probability based on a biophysical model.\n    \"\"\"\n    # Model parameters (concentrations in micromolar, uM)\n    K_d_c = 0.05  # Cytochrome c dissociation constant for Apaf-1 (uM)\n    K_d_a = 200.0  # ATP dissociation constant for Apaf-1 (uM)\n    K7_WT = 1.0e5  # Wild-type heptamerization equilibrium constant (uM^-6)\n    A_tot = 0.2    # Total Apaf-1 concentration (uM)\n\n    # Test cases: tuples of ([C], [T], gamma)\n    # [C]: Cytochrome c concentration (uM)\n    # [T]: ATP concentration (uM)\n    # gamma: Multiplicative factor for K7 due to mutation (dimensionless)\n    test_cases = [\n        (0.01, 2000.0, 1.0),\n        (0.5, 2000.0, 1.0),\n        (1.0, 2000.0, 1.0),\n        (0.5, 100.0, 1.0),\n        (1.0, 10.0, 1.0),\n        (0.5, 2000.0, 0.5),\n        (0.5, 2000.0, 0.1),\n        (0.0, 2000.0, 1.0),\n    ]\n\n    results = []\n    for case in test_cases:\n        C, T, gamma = case\n\n        # Step 1: Calculate activation probability (p_act)\n        # Probabilities of binding for cytochrome c and ATP\n        p_bind_c = C / (C + K_d_c)\n        p_bind_a = T / (T + K_d_a)\n        \n        # Total activation probability is the product of individual probabilities\n        p_act = p_bind_c * p_bind_a\n\n        # Handle the boundary case where no activation is possible\n        if p_act == 0.0:\n            P_assembly = 0.0\n            results.append(P_assembly)\n            continue\n            \n        # Step 2: Calculate total activated Apaf-1 concentration\n        A_act_tot = p_act * A_tot\n\n        # Step 3: Calculate the effective heptamerization equilibrium constant\n        K7_eff = gamma * K7_WT\n\n        # Step 4: Solve the mass balance equation for free activated monomer [A]\n        # The equation is: 7 * K7_eff * [A]^7 + [A] - A_act_tot = 0\n        def f(A):\n            return 7.0 * K7_eff * (A**7) + A - A_act_tot\n\n        # The root [A] must be in the interval [0, A_act_tot].\n        # brentq is a robust root-finding method for a single variable.\n        try:\n            A_free = brentq(f, 0, A_act_tot)\n        except ValueError:\n            # This case should not be reached if A_act_tot  0 as f(0) = 0\n            # and f(A_act_tot) = 0. Added for robustness.\n            A_free = 0.0\n\n        # Step 5: Calculate the apoptosome assembly probability P_assembly\n        # P_assembly = (7 * [H]) / A_act_tot = (A_act_tot - [A]) / A_act_tot\n        P_assembly = (A_act_tot - A_free) / A_act_tot\n        \n        # Append the formatted result\n        results.append(P_assembly)\n\n    # Final print statement in the exact required format.\n    # The list is formatted to have 6 decimal places per value,\n    # joined by commas, and enclosed in square brackets.\n    print(f\"[{','.join([f'{r:.6f}' for r in results])}]\")\n\nsolve()\n\n```", "id": "2602955"}, {"introduction": "Beyond individual molecular machines, it is crucial to understand the systems-level dynamics of entire pathways. This problem focuses on the kinetics of autophagy, modeling the consequences of its pharmacological inhibition by chloroquine. You will apply principles of physical chemistry—specifically acid-base equilibria and ion trapping—to predict the change in lysosomal pH and, consequently, the effect on enzyme activity and the dynamic accumulation of key autophagy markers over time. This exercise demonstrates how fundamental chemical principles can be used to quantitatively predict the time-dependent response of a complex cellular degradation system [@problem_id:2603011].", "problem": "A weakly basic lysosomotropic drug, chloroquine, is introduced into a mammalian cell culture at a constant cytosolic total concentration of $C_{0} = 1.00 \\times 10^{-4}$ mol/L. Treat chloroquine as a monoprotic weak base with acid dissociation constant $pK_{a}^{\\mathrm{B}} = 8.40$ for the equilibrium $\\mathrm{BH}^{+} \\rightleftharpoons \\mathrm{B} + \\mathrm{H}^{+}$ and assume only the neutral form $\\mathrm{B}$ crosses membranes rapidly. The cytosolic pH is clamped at $pH_{\\mathrm{cyt}} = 7.20$ by a large extracellular reservoir, and the lysosomal initial pH is $pH_{0} = 4.50$ with an intrinsic buffer capacity $\\beta = 3.0 \\times 10^{-2}$ mol/L per pH unit around this pH. Assume that the neutral species equilibrates across the lysosomal membrane so that its concentration is the same in the cytosol and in the lysosomal lumen, and that protonation inside the lysosomal lumen consumes free protons according to mass action. Neglect changes in cytosolic drug concentration due to lysosomal sequestration.\n\nConsider a representative lysosomal hydrolase whose catalytic activity requires a specific protonation state of two ionizable residues: residue $A$ must be protonated with $pK_{a,A} = 5.00$, and residue $B$ must be deprotonated with $pK_{a,B} = 4.00$. The active fraction of enzyme molecules is determined solely by the required ionization states of these two independent groups. Assume that the apparent first-order lysosomal degradation rate constant for cargo proteins is proportional to the active fraction of this hydrolase.\n\nAt baseline ($pH = pH_{0}$), the half-life of a generic lysosomal cargo protein is $t_{1/2,0} = 2.00$ h. For the autophagy markers microtubule-associated protein 1 light chain 3 (LC3)-II and p62/sequestosome 1 (p62), assume baseline first-order clearance half-lives $t_{1/2,L} = 0.500$ h and $t_{1/2,P} = 2.00$ h, respectively, and that their synthesis rates remain constant during chloroquine exposure. At time $t=0$, chloroquine is added and the lysosomal pH instantaneously begins to re-equilibrate to the new steady state due to proton binding by chloroquine; assume the new steady-state lysosomal pH is reached rapidly compared to the timescales of marker accumulation. From that time onward, the only change in LC3-II and p62 turnover is the pH-dependent reduction in their lysosomal degradation rate constants, with no change in synthesis.\n\nStarting only from fundamental definitions of acid–base equilibria, buffer capacity, and first-order kinetics, and the stated mechanistic assumptions:\n- Compute the new steady-state lysosomal pH after chloroquine exposure.\n- Using that pH, determine the new half-life of the generic lysosomal cargo protein.\n- Using that same pH-driven change in degradation rate constant, compute the fold-accumulation (ratio to the pre-treatment steady-state level) of LC3-II and p62 at time $T = 2.00$ h after chloroquine addition.\n\nRound your answers to three significant figures. Express the half-life in hours and the fold-accumulations as pure numbers (decimals). Report the final result as a single row vector in the order: new lysosomal pH, new generic cargo half-life (hours), LC3-II fold-accumulation at $T = 2.00$ h, p62 fold-accumulation at $T = 2.00$ h.", "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It contains all necessary information to derive a unique solution based on established principles of physical chemistry and cell biology. The parameter values are physiologically realistic. The problem is therefore deemed valid and we proceed with the solution.\n\nThe solution requires three main calculations: first, the new steady-state lysosomal pH ($pH_{new}$); second, the new half-life of a generic cargo protein ($t_{1/2, new}$); and third, the fold-accumulation of the autophagy markers LC3-II and p62.\n\n**1. Calculation of the New Lysosomal pH**\n\nFirst, we must determine the concentration of the neutral form of chloroquine, $\\mathrm{B}$, in the cytosol. This form is in rapid equilibrium across the lysosomal membrane. The equilibrium for the chloroquine conjugate acid is $\\mathrm{BH}^{+} \\rightleftharpoons \\mathrm{B} + \\mathrm{H}^{+}$, with $pK_{a}^{\\mathrm{B}} = 8.40$. The relationship between pH, $pK_a$, and the concentrations of the acid and conjugate base is given by the Henderson-Hasselbalch equation:\n$$pH = pK_{a} + \\log_{10}\\left(\\frac{[\\text{base}]}{[\\text{acid}]}\\right)$$\nIn the cytosol, with $pH_{\\mathrm{cyt}} = 7.20$, the acid is $\\mathrm{BH}^{+}$ and the base is $\\mathrm{B}$.\n$$7.20 = 8.40 + \\log_{10}\\left(\\frac{[\\mathrm{B}]_{\\mathrm{cyt}}}{[\\mathrm{BH}^{+}]_{\\mathrm{cyt}}}\\right)$$\n$$\\frac{[\\mathrm{B}]_{\\mathrm{cyt}}}{[\\mathrm{BH}^{+}]_{\\mathrm{cyt}}} = 10^{7.20 - 8.40} = 10^{-1.20}$$\nThe total concentration of chloroquine in the cytosol is given as $C_{0} = [\\mathrm{B}]_{\\mathrm{cyt}} + [\\mathrm{BH}^{+}]_{\\mathrm{cyt}} = 1.00 \\times 10^{-4}$ mol/L. We can solve for $[\\mathrm{B}]_{\\mathrm{cyt}}$:\n$$[\\mathrm{B}]_{\\mathrm{cyt}} = C_{0} - [\\mathrm{BH}^{+}]_{\\mathrm{cyt}} = C_0 - [\\mathrm{B}]_{\\mathrm{cyt}} \\cdot 10^{1.20}$$\n$$[\\mathrm{B}]_{\\mathrm{cyt}}(1 + 10^{1.20}) = C_{0}$$\n$$[\\mathrm{B}]_{\\mathrm{cyt}} = \\frac{1.00 \\times 10^{-4}}{1 + 10^{1.20}} \\approx 5.935 \\times 10^{-6} \\text{ mol/L}$$\nAccording to the problem statement, the neutral form equilibrates across the lysosomal membrane, so $[\\mathrm{B}]_{\\mathrm{lys}} = [\\mathrm{B}]_{\\mathrm{cyt}}$.\n\nInside the lysosome, the neutral base $\\mathrm{B}$ is protonated, consuming free protons and causing the pH to rise from its initial value of $pH_{0} = 4.50$. The amount of protons consumed per unit volume is equal to the concentration of the newly formed protonated drug, $[\\mathrm{BH}^{+}]_{\\mathrm{lys}}$. The change in pH is related to the amount of consumed protons via the buffer capacity, $\\beta = 3.0 \\times 10^{-2}$ mol/L per pH unit.\n$$[\\mathrm{BH}^{+}]_{\\mathrm{lys}} = \\beta \\cdot (pH_{new} - pH_{0})$$\nwhere $pH_{new}$ is the new steady-state lysosomal pH.\n\nAt this new pH, the Henderson-Hasselbalch equation must also hold within the lysosome:\n$$pH_{new} = pK_{a}^{\\mathrm{B}} + \\log_{10}\\left(\\frac{[\\mathrm{B}]_{\\mathrm{lys}}}{[\\mathrm{BH}^{+}]_{\\mathrm{lys}}}\\right)$$\n$$[\\mathrm{BH}^{+}]_{\\mathrm{lys}} = [\\mathrm{B}]_{\\mathrm{lys}} \\cdot 10^{(pK_{a}^{\\mathrm{B}} - pH_{new})}$$\nBy equating the two expressions for $[\\mathrm{BH}^{+}]_{\\mathrm{lys}}$, we obtain a single equation for $pH_{new}$:\n$$\\beta \\cdot (pH_{new} - pH_{0}) = [\\mathrm{B}]_{\\mathrm{cyt}} \\cdot 10^{(pK_{a}^{\\mathrm{B}} - pH_{new})}$$\nSubstituting the known values:\n$$3.0 \\times 10^{-2} \\cdot (pH_{new} - 4.50) = (5.935 \\times 10^{-6}) \\cdot 10^{(8.40 - pH_{new})}$$\nThis is a transcendental equation for $pH_{new}$. Letting $x = pH_{new}$, we have $0.03(x - 4.5) \\approx 1490.9 \\cdot 10^{-x}$. We solve this numerically. Testing $x=5.00$:\nLeft Hand Side (LHS): $0.03 \\cdot (5.00 - 4.50) = 0.015$.\nRight Hand Side (RHS): $(5.935 \\times 10^{-6}) \\cdot 10^{(8.40 - 5.00)} = (5.935 \\times 10^{-6}) \\cdot 10^{3.40} \\approx 0.01491$.\nThe values are very close. A numerical root-finding method (e.g., Newton-Raphson) gives a more precise value of $pH_{new} \\approx 4.9986$. Rounded to three significant figures, the new lysosomal pH is $5.00$.\n\n**2. Calculation of the New Generic Cargo Half-Life**\n\nThe degradation rate constant, $k$, is proportional to the active fraction of the hydrolase, $F_{active}$. The enzyme is active when residue A ($pK_{a,A} = 5.00$) is protonated and residue B ($pK_{a,B} = 4.00$) is deprotonated. The fractions of these states at a given pH are:\n$$f_{A, protonated} = \\frac{1}{1 + 10^{pH - pK_{a,A}}}$$\n$$f_{B, deprotonated} = \\frac{10^{pH - pK_{a,B}}}{1 + 10^{pH - pK_{a,B}}} = \\frac{1}{1 + 10^{pK_{a,B} - pH}}$$\nSince the two residues are independent, the active fraction is the product:\n$$F_{active}(pH) = f_{A, protonated} \\cdot f_{B, deprotonated} = \\left(\\frac{1}{1 + 10^{pH - 5.00}}\\right) \\left(\\frac{1}{1 + 10^{4.00 - pH}}\\right)$$\nWe calculate $F_{active}$ at the initial pH ($pH_{0} = 4.50$) and the new pH ($pH_{new} = 5.00$).\n$$F_{active}(4.50) = \\left(\\frac{1}{1 + 10^{4.50 - 5.00}}\\right) \\left(\\frac{1}{1 + 10^{4.00 - 4.50}}\\right) = \\left(\\frac{1}{1 + 10^{-0.5}}\\right) \\left(\\frac{1}{1 + 10^{-0.5}}\\right) \\approx 0.5772$$\n$$F_{active}(5.00) = \\left(\\frac{1}{1 + 10^{5.00 - 5.00}}\\right) \\left(\\frac{1}{1 + 10^{4.00 - 5.00}}\\right) = \\left(\\frac{1}{1 + 10^{0}}\\right) \\left(\\frac{1}{1 + 10^{-1}}\\right) = \\left(\\frac{1}{2}\\right) \\left(\\frac{1}{1.1}\\right) = \\frac{1}{2.2} \\approx 0.4545$$\nFor first-order kinetics, the half-life is $t_{1/2} = \\ln(2)/k$. Since $k$ is proportional to $F_{active}$, the half-life is inversely proportional to $F_{active}$.\n$$\\frac{t_{1/2, new}}{t_{1/2, 0}} = \\frac{k_{0}}{k_{new}} = \\frac{F_{active}(pH_{0})}{F_{active}(pH_{new})}$$\n$$t_{1/2, new} = t_{1/2, 0} \\cdot \\frac{F_{active}(4.50)}{F_{active}(5.00)} = 2.00 \\text{ h} \\cdot \\frac{0.5772}{0.4545} \\approx 2.00 \\text{ h} \\cdot 1.2699 \\approx 2.5398 \\text{ h}$$\nRounded to three significant figures, the new half-life is $2.54$ hours.\n\n**3. Calculation of LC3-II and p62 Fold-Accumulation**\n\nThe concentration $P(t)$ of a protein with constant synthesis rate $S$ and first-order degradation constant $k$ follows the differential equation $\\frac{dP}{dt} = S - kP$.\nAt initial steady state ($t0$), $\\frac{dP}{dt} = 0$, so the baseline level is $P_0 = S/k_0$.\nAt $t=0$, the degradation constant changes to $k_{new}$. The equation for $t \\ge 0$ is $\\frac{dP}{dt} = S - k_{new}P$, with initial condition $P(0) = P_0$.\nThe solution to this ODE is:\n$$P(t) = \\frac{S}{k_{new}} + \\left(P_0 - \\frac{S}{k_{new}}\\right)\\exp(-k_{new}t)$$\nSubstituting $P_0 = S/k_0$, we find the fold-accumulation $F(t) = P(t)/P_0$:\n$$F(t) = \\frac{P(t)}{P_0} = \\frac{k_0}{k_{new}} + \\left(1 - \\frac{k_0}{k_{new}}\\right)\\exp(-k_{new}t)$$\nLet $R = k_0/k_{new} = t_{1/2, new}/t_{1/2, 0} = 1.2699$. The formula is $F(t) = R - (R-1)\\exp(-k_{new}t)$. The degradation constants are related by $k_{new} = k_0/R$. For any protein, $k_0 = \\ln(2)/t_{1/2,0}$.\n\nFor LC3-II: $t_{1/2, L, 0} = 0.500$ h.\n$k_{L,0} = \\ln(2)/0.500 \\approx 1.386$ h$^{-1}$.\n$k_{L,new} = k_{L,0}/R \\approx 1.386/1.2699 \\approx 1.091$ h$^{-1}$.\nThe accumulation at $T = 2.00$ h is:\n$$F_{L}(2.00) = 1.2699 - (1.2699 - 1)\\exp(-1.091 \\times 2.00) = 1.2699 - (0.2699)\\exp(-2.182) \\approx 1.2699 - 0.0305 = 1.2394$$\nRounded to three significant figures, the fold-accumulation of LC3-II is $1.24$.\n\nFor p62: $t_{1/2, P, 0} = 2.00$ h.\n$k_{P,0} = \\ln(2)/2.00 \\approx 0.3466$ h$^{-1}$.\n$k_{P,new} = k_{P,0}/R \\approx 0.3466/1.2699 \\approx 0.2730$ h$^{-1}$.\nThe accumulation at $T = 2.00$ h is:\n$$F_{P}(2.00) = 1.2699 - (1.2699 - 1)\\exp(-0.2730 \\times 2.00) = 1.2699 - (0.2699)\\exp(-0.546) \\approx 1.2699 - 0.1563 = 1.1136$$\nRounded to three significant figures, the fold-accumulation of p62 is $1.11$.\n\nThe final results are presented as a single row vector.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n5.00  2.54  1.24  1.11\n\\end{pmatrix}\n}\n$$", "id": "2603011"}]}